Please assess the completion status of the following clinical trial:

Trial Title: Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of cancer~* Must be receiving single-agent capecitabine either in the adjuvant/neoadjuvant or palliative setting at a dose of ≥ 1000 mg/m² twice daily on days 1-14 (given in 3-week courses)~PATIENT CHARACTERISTICS:~* Life expectancy \> 12 weeks~* No preexisting neuropathy~* No known allergy to pyridoxine hydrochloride and its incipients~* No other dermatologic condition that, in the opinion of the physician, may affect the hands or feet or may complicate evaluation during study treatment~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior capecitabine~* Concurrent radiotherapy, steroids, and/or biological therapy (e.g., trastuzumab \[Herceptin®\] or bevacizumab) allowed provided they do not cause hand-foot syndrome (HFS)~* No other concurrent drugs (e.g., docetaxel or doxorubicin hydrochloride liposome) that can cause HFS~* No concurrent drugs (e.g., oxaliplatin or taxanes) that can cause neuropathy~* No concurrent pyridoxine hydrochloride-containing preparations (e.g., multivitamins or vitamin B complex)~* No concurrent over-the-counter products that contain urea or lactic acid~* No concurrent drugs reported to have drug interactions with pyridoxine hydrochloride (e.g., cycloserine; hydralazine; immunosuppressants; isoniazid; levodopa; estrogen or estrogen-containing contraceptives; penicillamine; phenobarbitone; phenytoin; or pyrazinamide)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pyridoxine hydrochloride (Type: ACTIVE_COMPARATOR): Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
- Placebo (Type: PLACEBO_COMPARATOR): Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).